Related Experiment Videos
[Coagulation factor VII--new physiopathological and therapeutic aspects]
C Helleberg1, E Hippe, J Ingerslev
1Medicinsk haematologisk afdeling, Amtssygehuset i Herlev.
Ugeskrift for Laeger
|August 22, 1994
Summary
Factor VII (FVII), a key protein in blood clotting, is vital for initiating coagulation. FVII deficiency can cause bleeding disorders, while its recombinant form (rFVIIa) shows therapeutic potential.
Area of Science:
- Biochemistry
- Hematology
Context:
- Factor VII (FVII) is a vitamin K-dependent glycoprotein synthesized in the liver, crucial for initiating blood coagulation.
- Its activation involves complex formation with tissue factor, playing a role in the extrinsic coagulation pathway.
Purpose:
- To present a revised hypothesis of blood coagulation.
- To discuss the implications of Factor VII activity in health and disease.
- To explore the therapeutic applications of recombinant Factor VIIa (rFVIIa).
Summary:
- Factor VII initiates coagulation and its altered activity is linked to atherogenesis and bleeding disorders.
- Recombinant FVIIa (rFVIIa) is investigated for treating hemophilia patients with inhibitors and for managing thrombocytopenia.
Impact:
- Understanding Factor VII's role is critical for diagnosing and managing coagulation disorders.
- Recombinant FVIIa offers potential therapeutic strategies for specific bleeding conditions.